September 2016
Volume 57, Issue 12
Open Access
ARVO Annual Meeting Abstract  |   September 2016
The effect of intravitreal injection of bevacizumab on the intraocular pressure in mexican population.
Author Affiliations & Notes
  • YOLANDA CHAVEZ ROMERO
    Ophthalmology, CIDOCS, ZAPOPAN, Jalisco, Mexico
  • Efrain Romo-Garcia
    Ophthalmology, CIDOCS, ZAPOPAN, Jalisco, Mexico
  • wilehaldo quiñonez
    Ophthalmology, CIDOCS, ZAPOPAN, Jalisco, Mexico
  • SILVIA PAZ
    Ophthalmology, CIDOCS, ZAPOPAN, Jalisco, Mexico
  • ABEL RAMON
    Ophthalmology, CIDOCS, ZAPOPAN, Jalisco, Mexico
  • PIMENTEL KARLA
    Ophthalmology, CIDOCS, ZAPOPAN, Jalisco, Mexico
  • Footnotes
    Commercial Relationships   YOLANDA CHAVEZ ROMERO, None; Efrain Romo-Garcia, None; wilehaldo quiñonez, None; SILVIA PAZ, None; ABEL RAMON, None; PIMENTEL KARLA, None
  • Footnotes
    Support  NONE
Investigative Ophthalmology & Visual Science September 2016, Vol.57, 6412. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to Subscribers Only
      Sign In or Create an Account ×
    • Get Citation

      YOLANDA CHAVEZ ROMERO, Efrain Romo-Garcia, wilehaldo quiñonez, SILVIA PAZ, ABEL RAMON, PIMENTEL KARLA; The effect of intravitreal injection of bevacizumab on the intraocular pressure in mexican population.. Invest. Ophthalmol. Vis. Sci. 2016;57(12):6412.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Purpose: The effect of intravitreal bevacizumab on the intraocular pressure (IOP) has been studied and it has been reported significant changes in the first 30 minutes with the dose of 0.05 ml, with no significant changes in the first 24 hours after the injection. In our study we measure the changes on IOP with the 0.1 ml dose of intravitreal bevacizumab in the first 24 hours in a mexican population.

Methods : Methods: We analyzed the records of all the subjects that received an intravitreal injection of bevacizumab (0.1 ml) in a period of 6 months in our hospital. We included all patients that came back to the 24-hours IOP measurement. We excluded patients with history of vitreoretinal surgery and silicon oil and patients with previous glaucoma treatment. We measured the IOP 30 min before the injection and 24 hours after the injection. The statistical analysis was performed with the paired samples t-test.

Results : Results: a total of 60 patients, 31 male and 29 female, 132 applications. The mean of age was 65.7 years. The pre-application IOP mean was 13.7±2.5 mmHg and the post-application IOP mean was 13.8±2.5 mmHg, with no statistical difference (p=0.530). The most common indications for the injections were Proloferative Diabetic Retinopathy with clinically significant macular edema (PDR + CSME) 38.2%, Non-proliferative Diabetic Retinopathy with clinically significant macular edema (NPDR + CSME) 23.3% and Age-related macular degeneration (ARMD) 20%.

Conclusions : Conclusions: The dose of 0.1 ml intravitreal injection of bevacizumab showed safety in the changes of the intraocular pressure in the period of 24 hours after the procedure.

This is an abstract that was submitted for the 2016 ARVO Annual Meeting, held in Seattle, Wash., May 1-5, 2016.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×